TNF and lymphoma: Over half a million patients have been treated with tumor necrosis factor (TNF)-α antagonists, but concerns regarding their safety have been raised worldwide [1].The most commonly reported adverse reactions to infliximab include acute or delayed hypersensitivity reactions; serious infections including reactivation of tuberculosis and hepatitis B virus; malignancy, especially lymphoma and hematologic reactions [2, 3].